Well3 Introduces Flat Rate Weight Loss Program for Sematglutide and Tirzepatide, starting at $159/mo.

Well3 is proud to unveil a new flat rate weight loss program, offering simplified pricing based on the amount of medicine required. This initiative is designed to make weight loss treatments more affordable and accessible, especially for individuals with modest weight loss goals.

Personalized Dosing for Affordable Care

Under the new flat rate model, patients will be able to pay a fixed monthly fee that aligns with their prescribed dosage of either Tirzepatide or Semaglutide, two leading medications used for weight management. The program offers tiered pricing based on the required dose, making it easier for patients to budget for their treatments:

Tirzepatide Pricing:

• Low to medium dose (2.5 to 5 mg): $259/month

• Higher dose (7.5 to 10 mg): $359/month

• Max dose (12.5 to 15 mg): $459/month

Semaglutide Pricing:

• Low to medium dose (up to 1 mg): $159/month

• Higher dose (up to 2 mg): $229/month

• Max dose (up to 4 mg): $329/month

Making Weight Loss Accessible for All

This flat rate program is especially beneficial for individuals with modest weight loss needs, who can now access lower doses of these medications at significantly reduced monthly costs. By aligning treatment with each patient's specific dosage requirements, Well3 ensures that those with smaller weight loss goals can pursue their health journey without the financial burden often associated with higher dose treatments.

Well3’s flat rate program simplifies the pricing structure, empowering more individuals to achieve their weight loss goals at a cost that fits their budget.